Development of phthalocyanines for photodynamic therapy

2006 ◽  
Vol 10 (09) ◽  
pp. 1116-1124 ◽  
Author(s):  
Shun-ichiro Ogura ◽  
Kenji Tabata ◽  
Kaoru Fukushima ◽  
Toshiaki Kamachi ◽  
Ichiro Okura

Photodynamic therapy is a method for treating several diseases, most notably cancer. Recent synthetic activity has created a number of phthalocyanines for potential use as photodynamic therapy photosensitizers. In this mini-review article, the background and the concepts in the development of new phthalocyanines are introduced.

Author(s):  
M. Saad Khan ◽  
Jangsun Hwang ◽  
Kyungwoo Lee ◽  
Yonghyun Choi ◽  
Kyobum Kim ◽  
...  

Microbubbles and nanobubbles can be prepared using various shells, such as phospholipids, polymers, proteins, and surfactants. They are echogenic and can be used as contrast agents for ultrasonic and photoacoustic imaging. These bubbles can be engineered in various sizes as vehicles for gas and drug delivery applications with novel properties and flexible structures. Hypoxic areas in tumors develop owing to an imbalance of oxygen supply and demand. In tumors, hypoxic regions have shown more resistance to chemotherapy, radiotherapy, and photodynamic therapies. The efficacy of photodynamic therapy depends on the availability of oxygen in the tumor to generate reactive oxygen species. Micro/nanobubbles have been shown to reverse hypoxic conditions and increase tissue oxygen levels. This review summarizes the synthesis methods and shell compositions of micro/nanobubbles and methods deployed for oxygen delivery. In addition, the shortcomings and prospects of engineering micro/nanobubbles are discussed for their potential use in photodynamic therapy.


2018 ◽  
Vol 47 (14) ◽  
pp. 4959-4967 ◽  
Author(s):  
Cynthia Al Hageh ◽  
Majd Al Assaad ◽  
Zeinab El Masri ◽  
Nawar Samaan ◽  
Mirvat El-Sibai ◽  
...  

An earth-abundant cuprous bis-phenanthroline photosensitizer showed potential use in the photodynamic therapy of cancer.


2009 ◽  
Vol 02 (01) ◽  
pp. 73-92 ◽  
Author(s):  
ZHENG HUANG ◽  
LIBO LI ◽  
HONGWEI WANG ◽  
XIULI WANG ◽  
KAIHUA YUAN ◽  
...  

Photodynamic therapy (PDT) has received increased attention since the regulatory approvals of several photosensitizers and light applicators in numerous countries and regions around the world. In recent years, much progress has been seen in basic research as well as clinical application. PDT clinical application has now extended from treating malignant diseases to nonmalignant diseases. This review article will present recent clinical data published in English journals. The data will be organized according to their clinical specialties. The new development and future direction in clinical applications of PDT for the management of both malignant and nonmalignant diseases will be discussed.


ChemInform ◽  
2010 ◽  
Vol 28 (49) ◽  
pp. no-no
Author(s):  
S. FOLEY ◽  
G. JONES ◽  
R. LIUZZI ◽  
D. J. MCGARVEY ◽  
M. H. PERRY ◽  
...  

1997 ◽  
Vol 75 (3) ◽  
pp. 262-275 ◽  
Author(s):  
Lifu Ma ◽  
David Dolphin

Starting from pheophorbide a methyl ester (5), a degradation product of chlorophyll a, routes for the preparation of 3-vinylporphyrins 6 and 9 and of an [A,C]-divinylporphyrin 16 are described. These porphyrins were obtained as a result of chemical modification of 5 on ring D and the exocyclic ring E. Diels–Alder reactions of these (di)vinylporphyrins with dimethyl acetylenedicarboxylate, to afford new regiochemically pure benzoporphyrin derivatives 29 and 30 and dibenzoporphyrin derivative 33 for potential use as sensitizers in photodynamic therapy of tumors, were also investigated. Keywords: Diels–Alder, (di)vinylporphyrins, (di)benzoporphyrins, photodynamic therapy, chlorophyll.


2019 ◽  
Vol 2 (2) ◽  
pp. 279-302 ◽  
Author(s):  
Subhadeep Banerjee ◽  
Jayeeta Sengupta ◽  
Ana Isabel Aljarilla ◽  
Francesca Setaro ◽  
Petri Makinen ◽  
...  

Diseases caused by obstruction or rupture of vulnerable plaques in the arterial walls such as cardiovascular infarction or stroke are the leading cause of death in the world. In the present work, we developed human serum albumin nanoparticles loaded by physisorption with zinc phthalocyanine, TT1, mainly used for industrial application as near-infrared photosensitizer and compared these to HSA NPs loaded with the well-known silicone phthalocyanine (Pc4). The use of NIR light allows for better tissue penetration, while the use of nanoparticles permits high local concentrations. The particles were characterized and tested for toxicity and stability as well as for their potential use as a contrast agent and NIR photosensitizer for photodynamic therapy in cardiovascular disease. We focused on the distribution of the nanoparticles in RAW264.7 macrophage cells and atherosclerotic mice. The nanoparticles had an average size of 120 nm according to dynamic light scattering, good loading capacity for zinc phthalocyanine, and satisfying stability in 50% (v/v) fetal bovine serum for 8 hours and in an aqueous environment at 4°C for 4–6 weeks. Under light irradiation we found a high production of singlet oxygen and the products showed no dark toxicity in vitro with macrophages (the target cells in vulnerable plaques), but at a low g/mL nanoparticle concentration killed efficiently the macrophages upon LED illumination. Injection of the contrast agent in atherosclerotic mice led to a visible fluorescence signal of zinc phthalocyanine in the atherosclerotic plaque at 30 minutes and in the lungs with a fast clearance of the nanoparticles. Zinc phthalocyanine loaded human serum albumin nanoparticles present an interesting candidate for the visualization and potentially photodynamic treatment of macrophages in atherosclerotic plaques.


2021 ◽  
Author(s):  
Pablo Vallecorsa ◽  
Gabriela Di Venosa ◽  
M. Belén Ballatore ◽  
Dario Ferreyra ◽  
Leandro Mamone ◽  
...  

Abstract Background: Photodynamic therapy (PDT) is an anticancer treatment that utilizes the interaction of light and a photosensitiser (PS), promoting tumour cell death mediated by generation of reactive oxygen species. In this study, we evaluated the in vitro photoactivity of four meso-substituted porphyrins and a porphyrin coupled to a fullerene. Methods: The cell line employed was the LM3 mammary adenocarcinoma, and the PS with the best photokilling activity was administered to mice bearing the LM3 subcutaneously implanted adenocarcinoma. The TEMCP4+ porphyrin and its analogue TEMCC4+ chlorine contain four identical carbazoyl substituents at the meso positions of the tetrapyrrolic macrocycle and have A4 symmetry. The TAPP derivative also has A4 symmetry, and it is substituted at the meso positions by aminopropoxy groups. The DAPP molecule has ABAB symmetry with aminopropoxy and the trifluoromethyl substituents in trans positions. The TCP-C604+ dyad is formed by a porphyrin unit covalently attached to the fullerene C60.Results: The PSs are taken up by the cells with the following efficiency: TAPP> TEMCP4+= TEMCC4+> DAPP >TCP-C604+, and the amount of intracellular PS correlates fairly with the photodamage degree, but also the quantum yields of singlet oxygen influence the PDT outcome. TAPP, DAPP, TEMCC4+ and TEMCP4+ exhibit high photoactivity against LM3 mammary carcinoma cells, being TAPP the most active. After topical application of TAPP on the skin of mice bearing LM3 tumours, the molecule is localized mainly in the stratum corneum, and at a lower extent in hair follicles and sebaceous glands. Systemic administration of TAPP produces a tumour: normal skin ratio of 31.4, and high accumulation in intestine and lung.Conclusion: The results suggest a potential use of topical TAPP for the treatment of actinic keratosis and skin adnexal neoplasms. In addition, selectivity for tumour tissue after systemic administration highlights the selectivity of and potentiality of TAPP as a new PS.


Author(s):  
Sarah Foley ◽  
Gurnos Jones ◽  
Raffaelle Liuzzi ◽  
David J. McGarvey ◽  
Martin H. Perry ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document